Artivion Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
30.1%projected annual EPS growth
Analyst Coverage
8analysts covering
FY Revenue (est.)
$490.3Mnext fiscal year
FY EPS (est.)
$0.44next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Adjusted Constant Currency Revenue Growth Quarterly1,200.0%Target: 7% to 11% for FY 2026
Adjusted EBITDA Quarterly22.1MTarget: $100 million to $107 million for FY 2026 (excluding Endospan)
Gross Margin Quarterly6,490.0%Target: Maintain or expand above 64%
Net Leverage Ratio Quarterly1.8xTarget: Maintain low leverage post-Endospan acquisition
Watch Items
- Endospan Integration and NEXUS U.S. Launch PreparationTrigger: U.S. commercial launch targeted for January 2027Action: Monitor integration expenses (estimated at $8 million for FY 2026) and clinical training progress.
- AMDS Starter-Set Sales and Hospital AdoptionTrigger: Slower initial stocking orders due to $100,000 upfront cost and IRB delaysAction: Track surgeon survey feedback and hospital purchasing approvals to gauge adoption acceleration.
- International Stent Graft Sales PerformanceTrigger: Softness in international markets and Latin America revenue decline (-23% YoY in Q1 2026)Action: Assess commercial execution and distributor performance in EMEA and Latin America.
Research as of 20 Jun 2026